PRISM BioLab (206A) · InitiativeFirst statedLatest Occurring Fact (2026-05-14): "Worsened"
¥106.3 million investment in analytical and testing equipment
First written in FY2025. 1 of 2 entries say "Worsened", first in 2026-05-14. Latest entry: 2026-05-14.
2entries
2years
1from disclosures
How it moved
Same theme, other companies
Capital Investment in Head Office Analytical and Testing EquipmentA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
PRISM BioLab moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Worsened".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- 2026-05-14WorsenedOccurring Fact
「For equipment newly installed during the second quarter accounting period of the fiscal year ending September 2026 (1 January 2026 to 31 March 2026), we reduced the carrying amount to the recoverable amount from a business revenue perspective and recorded an impairment loss of ¥24,290 thousand as an extraordinary loss.」
An impairment loss arose in connection with equipment investment intended to strengthen R&D functions, reducing the carrying amount of the equipment to its recoverable amount. The original equipment investment policy was unchanged, but the realized recoverability of the investment deteriorated. - FY2025First statedAnnual report
「Head office (Fujisawa, Kanagawa Prefecture) | Analytical and testing equipment | ¥106.3 million | Internal funds | October 2025 | July 2026」
To strengthen our research and development capabilities, we will invest ¥106.3 million in analytical and testing equipment at our head office, with completion scheduled for July 2026.